PA Consulting Group helped Novo Nordisk, one of the world's largest insulin manufacturers, to embark on an ambitious business strategy of becoming more than a developer of insulin and insulin delivery devices; to become a company that patients would turn to manage their diabetes - a ‘preferred diabetes company'.
Traditionally, Novo Nordisk's insulin developers had worked separately from those involved in delivering the insulin to the patient. To achieve the company's new focus on the patient, these two groups were brought together in a new division called Protein Delivery Systems.
PA helped overcome some major challenges including the integration of two existing groups and new recruits; alignment with the overall strategy; the creation of a unique culture; and progressing innovation.
"A year ago PDS was an idea, now it's business as usual."
Lars Guldbæk Karlsen Senior Vice President